{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:26:05Z","timestamp":1764433565866,"version":"3.40.5"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.gore.2024.101452","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T22:28:15Z","timestamp":1720304895000},"page":"101452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mirvetuximab after anaphylaxis to Paclitaxel: A case report"],"prefix":"10.1016","volume":"54","author":[{"given":"Megan A.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-6678","authenticated-orcid":false,"given":"Taylor A.","family":"Rives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gore.2024.101452_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"10.1016\/j.gore.2024.101452_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol."},{"issue":"1","key":"10.1016\/j.gore.2024.101452_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5528\/wjtm.v3.i1.1","article-title":"Epithelial ovarian cancer: An overview","volume":"3","author":"Desai","year":"2014","journal-title":"World J Transl Med."},{"issue":"1","key":"10.1016\/j.gore.2024.101452_b0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0091-6749(96)70281-6","article-title":"Successful parenteral desensitization to paclitaxel","volume":"97","author":"Essayan","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.gore.2024.101452_b0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","article-title":"Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments","volume":"96","author":"Feldweg","year":"2005","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.gore.2024.101452_b0030","article-title":"VENTANA FOLR1 (FOLR-2.1) RxDx Assay approval letter","volume":"AZNovember 14","author":"Food","year":"2022","journal-title":"Tucson"},{"issue":"2","key":"10.1016\/j.gore.2024.101452_b0035","first-page":"170","article-title":"Immunoglobulin E-Mediated Severe Anaphylaxis to Paclitaxel","volume":"20","author":"Garcia","year":"2010","journal-title":"J Investig Allergol Clin Immunol."},{"issue":"6","key":"10.1016\/j.gore.2024.101452_b0040","first-page":"583","article-title":"Taxol: an important new drug in the management of epithelial ovarian cancer","volume":"64","author":"Markman","year":"1991","journal-title":"Yale J Biol Med."},{"issue":"1","key":"10.1016\/j.gore.2024.101452_b0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol."},{"issue":"13","key":"10.1016\/j.gore.2024.101452_b0050","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.gore.2024.101452_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.gore.2024.101452_b0060","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol."},{"key":"10.1016\/j.gore.2024.101452_b0065","volume":"41(17):1","author":"Moore","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.gore.2024.101452_b0070","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/all.15113","article-title":"Hypersensitivity reactions to chemotherapy: an EEACI Position Paper","volume":"77","author":"Pagani","year":"2021","journal-title":"European Academy of Allergy and Clinical Immunology."},{"issue":"3","key":"10.1016\/j.gore.2024.101452_b0075","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2014.0040","article-title":"Chemotherapy hypersensitivity reactions in ovarian cancer","volume":"12","author":"Picard","year":"2014","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"10.1016\/j.gore.2024.101452_b0080","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejps.2011.09.016","article-title":"Complement activation by polyehtoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20","volume":"45","author":"Weiszhar","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.gore.2024.101452_b0085","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol Rep."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924001310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924001310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:34:37Z","timestamp":1722238477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578924001310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":17,"alternative-id":["S2352578924001310"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2024.101452","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirvetuximab after anaphylaxis to Paclitaxel: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2024.101452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101452"}}